212 related articles for article (PubMed ID: 37365915)
1. Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial.
Lee B; Ji W; Lee JC; Song SY; Shin YS; Cho YH; Park JE; Park H; Choi CM
Thorac Cancer; 2023 Aug; 14(22):2233-2237. PubMed ID: 37365915
[TBL] [Abstract][Full Text] [Related]
2. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
[TBL] [Abstract][Full Text] [Related]
3. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
[TBL] [Abstract][Full Text] [Related]
4. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
[TBL] [Abstract][Full Text] [Related]
5. Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.
Li A; Chen HJ; Yang JJ
Clin Lung Cancer; 2023 Jan; 24(1):82-88. PubMed ID: 36333268
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
[TBL] [Abstract][Full Text] [Related]
8. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
11. Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment.
Acker F; Aguinarte L; Althoff F; Heinzen S; Rost M; Wild P; Reiser L; Mänz M; Meyer F; Stratmann J; Sebastian M
Clin Lung Cancer; 2022 Nov; 23(7):e473-e477. PubMed ID: 36089483
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
13. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
14. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
15. Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.
Kim H; Ahn BC; Lee J; Lee JB; Hong MH; Kim HR; Cho BC; Lim SM
Lung Cancer; 2023 Jun; 180():107213. PubMed ID: 37104879
[TBL] [Abstract][Full Text] [Related]
16. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY
Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
Yu HA; Goldberg SB; Le X; Piotrowska Z; Goldman JW; De Langen AJ; Okamoto I; Cho BC; Smith P; Mensi I; Ambrose H; Kraljevic S; Maidment J; Chmielecki J; Li-Sucholeiki X; Doughton G; Patel G; Jewsbury P; Szekeres P; Riess JW
Clin Lung Cancer; 2021 Nov; 22(6):601-606. PubMed ID: 34389237
[TBL] [Abstract][Full Text] [Related]
18. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A; Wang J; Wang Y; Lee SH; Melosky B; Shih JY; Wang J; Azuma K; Juan-Vidal O; Cobo M; Felip E; Girard N; Cortot AB; Califano R; Cappuzzo F; Owen S; Popat S; Tan JL; Salinas J; Tomasini P; Gentzler RD; William WN; Reckamp KL; Takahashi T; Ganguly S; Kowalski DM; Bearz A; MacKean M; Barala P; Bourla AB; Girvin A; Greger J; Millington D; Withelder M; Xie J; Sun T; Shah S; Diorio B; Knoblauch RE; Bauml JM; Campelo RG; Cho BC;
Ann Oncol; 2024 Jan; 35(1):77-90. PubMed ID: 37879444
[TBL] [Abstract][Full Text] [Related]
19. A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).
Kim KH; Yoon S; Ahn HK; Lee SY; Lee GW; Lee SS; Cho JH; Cho BC; Yoon HI; Lim SM
Clin Lung Cancer; 2022 Dec; 23(8):e536-e539. PubMed ID: 36002368
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
